Tvardi Therapeutics, Inc. (TVRD)Healthcare | Biotechnology | Sugar Land, United States | NasdaqCM
3.31 USD
+0.03
(0.915%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.32 +0.01 (0.242%) ⇧ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:33 a.m. EDT
The immediate catalyst is undeniable: the company just announced positive Phase 1 data for its STAT3 inhibitor, triggering a massive intraday rally and a 149% weekly gain. This clinical validation transforms the narrative from speculative cash burn to potential pipeline value, justifying the aggressive call option positioning seen in the data. However, the long-term outlook remains precarious due to the company's deep structural issues. Despite the recent price recovery, the stock is still down roughly 85% from its peak nine years ago, and the business continues to bleed cash with negative free cash flow and no earnings. The balance sheet is fragile, with cash reserves barely covering operations while debt sits on the books. While the short-term momentum is clearly bullish based on the clinical data and options flow, the long-term investment case is neutral at best; the company has survived a decade of decline and now faces the high-stakes reality of Phase 2 execution. Investors should view this as a high-risk momentum play on a binary event rather than a stable compounder. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.163080 |
| AutoARIMA | 0.192751 |
| AutoETS | 0.192752 |
| MSTL | 0.193963 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.037 |
| Excess Kurtosis | 0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.2 |
| Market Cap | 31,052,252 |
| Forward P/E | -1.21 |
| Website | https://tvarditherapeutics.com |
As of July 11, 2026, 3:33 a.m. EDT: Speculators are positioning for a volatile breakout above $5.00, evidenced by massive open interest in out-of-the-money calls at that strike compared to the current price of $3.28. Conversely, put writers are heavily concentrated at the $5.00 level, suggesting a 'pin risk' or a specific resistance ceiling where sellers expect the rally to stall. Implied volatility is elevated for near-term expirations, reflecting uncertainty around the upcoming Phase 2 trial plans.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.89004356 |
| Address1 | 3 Sugar Creek Center Boulevard |
| Address2 | Suite 525 |
| All Time High | 1,067.292 |
| All Time Low | 1.5 |
| Ask | 3.81 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 12,738,900 |
| Average Daily Volume3 Month | 2,131,224 |
| Average Volume | 2,131,224 |
| Average Volume10Days | 12,738,900 |
| Bid | 2.4 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 1.546 |
| City | Sugar Land |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.31 |
| Current Ratio | 2.25 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.415 |
| Day Low | 2.93 |
| Debt To Equity | 1.2 |
| Display Name | Tvardi Therapeutics |
| Earnings Timestamp | 1,778,243,400 |
| Earnings Timestamp End | 1,778,243,400 |
| Earnings Timestamp Start | 1,778,243,400 |
| Ebitda | -29,350,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.213 |
| Enterprise Value | 6,245,248 |
| Eps Current Year | -2.34286 |
| Eps Forward | -2.72857 |
| Eps Trailing Twelve Months | -0.27 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.1318 |
| Fifty Day Average Change | 0.1782 |
| Fifty Day Average Change Percent | 0.05690019 |
| Fifty Two Week Change Percent | -89.00436 |
| Fifty Two Week High | 43.65 |
| Fifty Two Week High Change | -40.34 |
| Fifty Two Week High Change Percent | -0.9241695 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 1.81 |
| Fifty Two Week Low Change Percent | 1.2066666 |
| Fifty Two Week Range | 1.5 - 43.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,391,178,600,000 |
| Float Shares | 5,671,304 |
| Forward Eps | -2.72857 |
| Forward P E | -1.2130896 |
| Free Cashflow | -11,570,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.34642 |
| Held Percent Institutions | 0.28933 |
| Implied Shares Outstanding | 9,381,345 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,761,600 |
| Last Split Factor | 1:3 |
| Long Business Summary | Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas. |
| Long Name | Tvardi Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 31,052,252 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_570288312 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -15,439,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 30,395,554 |
| Number Of Analyst Opinions | 8 |
| Open | 3.2 |
| Operating Cashflow | -21,669,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 713 489 8654 |
| Post Market Change | 0.008000135 |
| Post Market Change Percent | 0.24169594 |
| Post Market Price | 3.318 |
| Post Market Time | 1,783,987,179 |
| Previous Close | 3.28 |
| Price Eps Current Year | -1.4128032 |
| Price Hint | 4 |
| Price To Book | 2.141009 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.219 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.77778 |
| Region | US |
| Regular Market Change | 0.03 |
| Regular Market Change Percent | 0.914633 |
| Regular Market Day High | 3.415 |
| Regular Market Day Low | 2.93 |
| Regular Market Day Range | 2.93 - 3.415 |
| Regular Market Open | 3.2 |
| Regular Market Previous Close | 3.28 |
| Regular Market Price | 3.31 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,228,668 |
| Return On Assets | -0.68635005 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 9,381,344 |
| Shares Percent Shares Out | 0.0541 |
| Shares Short | 507,431 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 436,072 |
| Short Name | Tvardi Therapeutics, Inc. |
| Short Percent Of Float | 0.0544 |
| Short Ratio | 1.36 |
| Source Interval | 15 |
| State | TX |
| Symbol | TVRD |
| Target High Price | 15.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 9.75 |
| Target Median Price | 10.0 |
| Total Cash | 24,981,000 |
| Total Cash Per Share | 2.663 |
| Total Debt | 174,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.258125 |
| Two Hundred Day Average Change | -2.948125 |
| Two Hundred Day Average Change Percent | -0.47108757 |
| Type Disp | Equity |
| Volume | 2,228,668 |
| Website | https://tvarditherapeutics.com |
| Zip | 77,478 |